Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Nitric Oxide Footbath for Treatment of Diabetic Foot Ulcers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04755647
Recruitment Status : Recruiting
First Posted : February 16, 2021
Last Update Posted : February 24, 2021
Sponsor:
Information provided by (Responsible Party):
Sanotize Research and Development corp.

Brief Summary:
The purpose of this study is to investigate the safety and effectiveness of a nitric oxide releasing solution, delivered as a footbath, to act as an antimicrobial treatment for participants presenting with a diabetic foot ulcer.

Condition or disease Intervention/treatment Phase
Diabetic Foot Ulcer Drug: Nitric Oxide-Releasing Solution Drug: Saline solution, hypotonic Phase 1 Phase 2

Detailed Description:
It is hypothesized that a single, relatively short exposure (three times a week for a half hour) of a nitric oxide releasing solution (NORS) for four (4) week period will be well tolerated and may have other beneficial secondary outcomes for individuals presenting with diabetic foot ulcers.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This is a single-center, randomized, placebo controlled parallel group,clinical safety study comparing an investigational drug add-on to a placebo control. Up to 40 participants with mildly infected neuropathic or non-neuropathic or neuro-ischemic diabetic foot ulcers will be enrolled.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Packaging will be generic, coded and indistinguishable from placebo.
Primary Purpose: Treatment
Official Title: Safety & Efficacy of Topical Nitric Oxide Releasing Solution (NORS) Delivered as an Adjunctive Footbath Treatment as Compared to Placebo in the Management of Diabetic Foot Ulcers
Actual Study Start Date : February 23, 2021
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : May 30, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Nitric Oxide-Releasing Solution (NORS)
Five litre foot bath delivery NORS
Drug: Nitric Oxide-Releasing Solution
Active antimicrobial

Placebo Comparator: Saline
Five litre foot bath delivery NORS
Drug: Saline solution, hypotonic
Placebo




Primary Outcome Measures :
  1. To measure the number of participants discontinued or lost to follow-up in the NORS compared to hypotonic saline in participants with diabetic foot ulcers (DFU) [ Time Frame: 28 days ]
    Proportion of participants lost-to-follow-up, discontinuing study treatment due to intolerance or adverse events, or initiating new medications or treatments, or leaving/discontinuing the study for any other reason

  2. To measure the severity of adverse events of NORS compared to hypotonic saline in participants with DFU [ Time Frame: 29 days ]
    Severity as measured by adverse event scale (1-5) and frequency of adverse events that results in discontinuation of the investigative treatment.

  3. To measure the negative changes in laboratory values of NORS compared to hypotonic saline with DFU [ Time Frame: 29 days ]
    Proportion of negative laboratory changes resulting in discontinuation of investigative treatments.

  4. To measure the negative changes in vital sign during NORS compared to hypotonic saline administration in participants with DFU [ Time Frame: 29 days ]
    Proportion of subjects with deterioration in vital signs resulting in discontinuation of investigative treatment.

  5. To measure worsening of wound infection during NORS compared to hypotonic saline administration in participants with DFU [ Time Frame: 29 days ]
    Proportion of subjects with incidence of infection resulting in discontinuation of the investigative treatment.

  6. To measure worsening of wound area during NORS compared to hypotonic saline administration in participants with DFU [ Time Frame: 29 days ]
    Proportion of subjects with increased wound area resulting in discontinuation of the investigative treatment.

  7. To measure the methemoglobin percent level during NORS compared to hypotonic saline administration in participants withe DFU [ Time Frame: 29 days ]
    Proportion of subjects with an increase in methemoglobin percent level resulting in discontinuation of the investigative treatment.


Secondary Outcome Measures :
  1. To measure the efficacy of NORS compared to placebo on the change in pathogen load in participants with DFU [ Time Frame: 29 days ]
    Mean change in pathogen density as measured by colony forming units per milliliter (cfu/mL) compared to control

  2. To measure the efficacy of NORS compared to placebo on the change in bacterial load (CFU/mL) in participants with DFU [ Time Frame: 29 days ]
    Proportion of participants with a reduction in bacterial load as compared to control

  3. To measure the efficacy of NORS compared to placebo on the reduction of the number of clinical signs of infection in participants with diabetic foot ulcers (DFU) [ Time Frame: 29 days ]
    Proportion of participants with Clinical Response defined as resolution of one or more clinical signs of infection reported compared to control

  4. To measure the efficacy of NORS compared to placebo on the change in wound bacterial microbiota (species) in participants with DFU [ Time Frame: 29 days ]
    Mean changes in percentage of bacterial microbiota (species) will be determined by comparing to control

  5. To measure the efficacy of NORS compared to placebo on the change in wound area in participants with DFU [ Time Frame: 29 days ]
    Mean % change in wound area calculated for DFU compared to control



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Non-hospitalized, ambulatory patients with controlled diabetes mellitus as determined by physician diagnosis recorded in the medical record. Diabetes may be treated with insulin, oral hypoglycemic agents or diet alone. Patient glycaemic control (HbA1c) should be less than or equal to 12 % within 2 weeks of enrollment;
  2. Must be ≥ 19 years of age unless local laws dictate otherwise;
  3. Participants must be considered reliable, willing and able to give signed informed consent, and sign the informed consent form.
  4. English speaking (no translated documents are provided for this study);
  5. Participants must have either:

    i) 1 or more full thickness ulcers on the foot below the malleoli with a surface area exceeding 0.5 cm2 (50 mm2) after debridement (full thickness means extending through the epidermis and dermis but not involving tendon, bone, or joint capsule); or ii) 1 or more partial thickness ulcers (i.e., do not completely penetrate the dermis) of forefoot or digits; or iii) 1 or more ulcers of the forefoot or digits have granulation tissue at their base.

  6. Participants must have localized mild infection of at least 1 ulcer that would ordinarily be treated on an outpatient basis. Mild infection of an ulcer is defined by the presence of at least 2 manifestations of inflammation (purulence, erythema, pain, tenderness, warmth, or induration) which is limited to the skin or superficial subcutaneous tissues. If there is more than one ulcer meeting eligibility, the Investigator will determine which ulcer will be followed for the course of the study.
  7. Mild infection defined by IDSA criteria34:

    i) "Local infection involving only the skin and the subcutaneous tissue (without involvement of deeper tissues and without systemic signs as described below).

    ii) If erythema, must be >0.5 cm to ≤2 cm around the ulcer. Exclude other causes of an inflammatory response of the skin (e.g., trauma, gout, acute Charcot neuro-osteoarthropathy, fracture, thrombosis, venous stasis)."

  8. Participants who have been previously treated or are currently under treatment for a localized infection of an ulcer may be enrolled if there has been an inadequate response to treatment and the ulcer is still infected as described above.
  9. Participants must have a radiograph (appropriate views as determined by the investigator) within the 2 weeks prior to entry showing no evidence of cortical destruction consistent with osteomyelitis in the affected foot.
  10. Participants must have either:

    i) A palpable dorsalis pedis or posterior tibial pulse in the affected foot; or ii) If the pulse is congenitally absent or not palpable due to edema, a Dopplerable dorsalis pedis or posterior tibial pulse measured at ≥ 30 mm Hg; or iii) If there are no palpable pulses, non Dopplerable pulses, rest pain, or claudication on walking less than one block are present, the patient may be enrolled only if a vascular surgeon has determined that vascular surgery, angioplasty or amputation is not warranted.

  11. Participants must have no more than a reduced wound area of ≤30% documented by the PI, during the 2 weeks of screening, in which patients received institutional standard of care (SOC)
  12. Participants may not be taking or have received any other investigational therapy or approved therapy (i.e., drug or device) for investigational use within the 30 days prior to entry.
  13. Female Participants must be postmenopausal for at least 6 months; surgically sterilized (hysterectomy or tubal ligation); or, if of child-bearing potential, must have a negative pregnancy test prior to entry and must be willing to use one highly effective birth control method which include: hormonal contraceptives (e.g. combined oral contraceptives, patch, vaginal ring, injectables, and implants); intrauterine device (IUD) or intrauterine system (IUS); vasectomy and tubal ligation or to use two forms of effective birth control methods which include: barrier methods of contraception (e.g. male condom, female condom, cervical cap, diaphragm, contraceptive sponge). The Participants must have used the birth control method for at least 2 complete menstrual cycles prior to study entry.

Exclusion Criteria:

  1. Participants with limb threatening infection, extensive cellulitis (≥2 cm beyond the ulcer), lymphangitis, fasciitis, deep tissue infection, an abscess, or other evidence of local complications of infection.
  2. Participants with symptoms of systemic infection (e.g., severe hyperglycemia, ketoacidosis, azotemia).
  3. Participants requiring concurrent local or systemic antimicrobials during the study period for any infection, including diabetic foot ulcer.
  4. Participants who are currently treated by dialysis, awaiting dialysis or who have an estimated glomerular filtration rate of ≤60 mL/min/173 m2.
  5. Participants who are expected to be unable to care for their ulcer because of hospitalization, vacation, disability, etc. during the study period.
  6. Participants with known active alcohol or substance abuse within the 6 months preceding study entry.
  7. Participants who are receiving systemic corticosteroids (in a dose equivalent to ≥ 20 mg of prednisone per day) immunosuppressive radiation therapy, or cytotoxic agents
  8. Participants who require treatment for a primary or metastatic malignancy (other than squamous or basal cell carcinoma of the skin).
  9. Participants with a systemically immunocompromising disease, such as acquired immune deficiency syndrome or known human immunodeficiency virus (HIV) positivity.
  10. Participants who have an unexplained fever or chills during the week prior to enrollment.
  11. Participants with other conditions considered by the investigator to be reasons for disqualification that may jeopardize patient safety or interfere with the objectives of the trial (e.g., acute illness or exacerbation of chronic illness, lack of motivation, history of poor compliance).
  12. Women who are breast feeding, pregnant or attempting to become pregnant.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04755647


Contacts
Layout table for location contacts
Contact: Ruth A Hollet 604-589- 5234 achillesfoothealthcentre@gmail.com

Locations
Layout table for location information
Canada, British Columbia
Achilles Foot Health Centre Recruiting
Vancouver, British Columbia, Canada
Contact: Ruth Hollet    604-589-5234      
Contact       achillesfoothealthcentre@gmail.com   
Sponsors and Collaborators
Sanotize Research and Development corp.
Investigators
Layout table for investigator information
Principal Investigator: Scott Schumacher, MD Achilles Foot Health Centre
Layout table for additonal information
Responsible Party: Sanotize Research and Development corp.
ClinicalTrials.gov Identifier: NCT04755647    
Other Study ID Numbers: DFU-CTP-01
First Posted: February 16, 2021    Key Record Dates
Last Update Posted: February 24, 2021
Last Verified: February 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Sanotize Research and Development corp.:
nitric oxide
diabetic wounds
diabetic foot ulcer
drug resistent wound
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetic Foot
Foot Ulcer
Ulcer
Pathologic Processes
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Leg Ulcer
Skin Ulcer
Skin Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Diabetic Neuropathies
Foot Diseases
Nitric Oxide
Pharmaceutical Solutions
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Free Radical Scavengers
Antioxidants
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Endothelium-Dependent Relaxing Factors
Vasodilator Agents
Gasotransmitters